EGFR and neoplasm: For example, gefitinib cannot co-bind with JBJ-125 and is antagonistic in our biochemical assay but may nevertheless synergize with JBJ-125 via more potent inhibition of certain EGFR alleles that may arise due to tumor heterogeneity or in the context of EGFR amplification.